Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apabetalone in ESRD Patients on Hemodialysis
NCT03160430Phase 2Not yet recruiting
- Sponsor
- Resverlogix Corp.
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of apabetalone in end stage renal disease (ESRD), sponsored by Resverlogix Corp.. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
apabetalone
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT03160430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03160430.